EZH2 and hepatocellular carcinoma: EZH2-mediated, epigenetic silencing of Wnt antagonists constitutively activates WNT/β-CATENIN signaling, leading to HCC proliferation through de-repression of the growth-suppressive AXIN2, NKD1, PPP2R2B, PRICKLE1, and SFRP5 (26).